替格瑞洛和氯吡格雷对老年急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后并发症及预后的影响

doi:10.3969/j.issn.1006-6233.2021.02.029

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1207 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To compare the effects of ticagrelor and clopidogrel on postoperative complications and prognosis in elderly patients (aged ≥ 60 years) with ASTEMI after emergency PCI. Methods: 108 elderly patients with ASTEMI who underwent emergency PCI in our hospital from April 2017 to April 2019 were randomly divided by simple random grouping method into control group receiving loading dose of clopidogrel and study group receiving loading dose of ticagrelor, with 54 cases in each group. Blood flow classification before and after TIMI, postoperative no-reflow and malignant arrhythmia, dyspnea, hemorrhage and MACE3 months after surgery were compared between the two groups. Results: The proportion of TIMI grade 3 (92.59%) in the study group was significantly increased in comparison of the control group (75.93%), and the incidence rate of no-reflow and slow reflow (7.41%) was significantly decreased in comparison of the control group (25.93%) (P<0.05). The incidence rate of stent thrombosis, recurrent myocardial infarction and cardiac death in the study group was significantly decreased in comparison of the control group within 3 months after operation (all P<0.05), but there was no significant difference in the incidence rate of stroke between the two groups (P>0.05). There was no significant difference in the incidence rate of malignant arrhythmia, upper gastrointestinal bleeding and intracranial hemorrhage between the two groups within 3 months after operation (P>0.05). Conclusion: The antithrombotic therapy with ticagrelor in elderly patients with ASTEMI undergoing emergency PCI has definite clinical efficacy and good safety, and can effectively improve the prognosis.

Key words： Acute ST-segment elevation myocardial infarction Percutaneous coronary intervention Clopidogrel Ticagrelor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TIAN Feng
	BAI Xiaomei
	WANG Guidong

Cite this article:

TIAN Feng,BAI Xiaomei,WANG Guidong. Effects of Ticagrelor and Clopidogrel on Postoperative Complications and Prognosis in Elderly Patients with Acute ST-Segment Elevation Myocardial Infarction After Emergency Percutaneous Coronary Intervention[J]. HeBei Med, 2021, 27(2): 313-317.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.02.029 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I2/313

[1] Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart,2017,39(2):119~177.
[2] Venetsanos D,Lawesson SS,Alfredsson J,et al. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international,prospective,randomised administration of ticagrelor in the catheterisation laboratory or in the ambulance for new ST elevation myocardial Infarction to open the coronary artery (ATLANTIC) trial:a prespecified analysis[J]. BMJ Open,2017,7(9):e015241.
[3] Lozano I,Rondan J,Vegas JM,et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction:Analysis by subgroups[J].Am Coll Cardiol,2018,71(1):107~108.
[4] 胡建国.冠心病患者行PCI术后6个月应用低剂量替格瑞洛的临床疗效[J].中国实用医刊,2018,45(6):114~117.
[5] Kilic S,Fabris E,van't Hof AWJ,et al. Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction:findings from the ATLANTIC trial[J]. Am Heart,2018,196(1):1~8.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675~690.
[7] Alexopoulos D,Barampoutis N,Gkizas V,et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients:a randomized pharmacokinetic/pharmacodynamic study[J]. Clin Pharmacokinet,2016,55(3):359~367.
[8] 杜剑,高海燕.替格瑞洛联合依诺肝素对非ST段抬高性急性冠状动脉综合征的疗效评价[J].实用临床医药杂志,2019,23(5):53~55,59.
[9] 欧武华,欧阳武雄.新型抗血栓药物替格瑞洛对PCI术后患者出血风险的评估[J].实用药物与临床,2017,20(7):773~776.
[10] 张骏,罗晓丽,杨小利,等.替格瑞洛联合替罗非班对PCI术后STEMI患者临床疗效及短期预后的影响[J].心血管康复医学杂志,2017,26(4):405~409.
[11] Kohlhauer M,Dawkins S,Costa ASH,et al. Metabolomic profiling in acute ST-segment-elevation myocardial infarction identifies succinate as an early marker of human ischemia-reperfusion injury[J].Am Heart Assoc,2018,7(8):e007546.
[12] 张立敏,王伟群,张明亮,等.替格瑞洛及氯吡格雷对经皮冠状动脉介入治疗急性非ST段抬高型心肌梗死患者炎性因子的影响[J].中国老年学杂志,2018,38(9):2066~2067.
[13] 敬锐,林文华.替格瑞洛在急性心肌梗死患者急诊经皮冠状动脉介入治疗中的应用[J].中国医药,2016,11(9):1279~1282.
[14] Silvain J,Storey RF,Cayla G,et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction[J]. Thromb Haemost,2016,116(8):369~378.